QDEL Q1 Deep Dive: Softer Respiratory Demand and China Headwinds Drive Guidance Reset

Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) fell short of the market’s revenue expectations in Q1 CY2026, with sales falling 10.5% year on year to $619.8 million. The company’s full-year revenue guidance of $2.73 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP loss of $0.04 per share was significantly below analysts’ consensus estimates.

Is now the time to buy QDEL? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

QuidelOrtho’s first quarter was marked by notable headwinds, as management pointed to a significantly milder and shorter respiratory illness season compared to the prior year and highlighted disruptions in China linked to anticipated changes in diagnostic pricing guidelines. CEO Brian J. Blaser noted, “Our first quarter results were impacted by a significantly softer respiratory season…with influenza-like illness visits down approximately 30%.” Management also cited broader macroeconomic and geopolitical pressures, including order delays in the Middle East, as contributors to the company’s weaker performance.

Looking ahead, QuidelOrtho’s updated guidance reflects management’s caution in the face of ongoing uncertainty in both respiratory testing demand and China market dynamics. CFO Joseph M. Busky emphasized the company’s focus on cost mitigation and operational efficiency, noting, “We are confident in our EBITDA margin goals and the timeline for them,” despite reimbursement headwinds in China. The company is leaning on new product launches, such as the Lex Diagnostics platform and the high-sensitivity troponin assay, to drive growth and offset near-term challenges.

Key Insights from Management’s Remarks

Management attributed the quarter’s underperformance to a combination of weak respiratory testing trends, delayed orders in key regions, and anticipated regulatory changes in China.

• Respiratory testing decline: The softer and shorter respiratory illness season led to a sharp drop in demand for influenza and COVID-related diagnostic tests, with CEO Brian J. Blaser highlighting a 30% reduction in influenza-like illness visits versus last year.
• China sales slowdown: Distributors in China paused inventory purchases ahead of expected national pricing guideline changes for in vitro diagnostics (IVD), leading to lower revenue contributions from this market and increased uncertainty around future pricing and volumes.
• Order delays in the Middle East: Ongoing geopolitical disruptions caused delays in some tenders and orders, with management expecting a resumption if regional stability improves later in the year.
• Core labs and immunohematology resilience: Despite overall weakness, core laboratory and immunohematology segments showed stability, especially in North America and select international markets, supporting the company’s broader revenue base.
• Lex Diagnostics acquisition: The completed acquisition of Lex Diagnostics adds an ultrafast molecular platform, with early customer interest and manufacturing scale-up underway. However, management clarified that measurable assay pull-through and associated revenue from Lex are not expected until early 2027, positioning the company for future growth in point-of-care diagnostics.

Drivers of Future Performance

QuidelOrtho’s forward outlook centers on the pace of recovery in core diagnostic volumes, the impact of China’s evolving regulatory landscape, and the ramp-up of new product launches.

• China regulatory impact: Management expects distributor caution in China to continue into the first half, with potential stabilization later in the year. The timing and specifics of national pricing changes remain a risk, but QuidelOrtho aims to mitigate the impact through operational and cost efficiencies.
• Product innovation and launches: The rollout of the Lex Diagnostics platform and new assays, including the high-sensitivity troponin test and VITROS 450 platform, are expected to drive mid-single-digit growth in the labs segment specifically and bolster the company’s margin profile as molecular diagnostics become a larger revenue contributor.
• Cost containment and margin initiatives: Ongoing efforts—including staffing reductions, procurement improvements, and facility consolidation—are designed to expand adjusted EBITDA margin. Management reiterated confidence in achieving mid- to high-20% margins by 2027, aided by the exit of lower-margin businesses and scale-up of higher-margin molecular offerings.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will closely monitor (1) the stabilization of Chinese distributor order patterns and clarity on national IVD pricing guidelines, (2) ramp-up and customer adoption of new molecular and cardiac diagnostic platforms like Lex Diagnostics and the high-sensitivity troponin assay, and (3) the pace and effectiveness of cost reduction and facility consolidation initiatives. Execution in these areas will be essential for regaining financial momentum.

QuidelOrtho currently trades at $11.58, in line with $11.66 just before the earnings. Is there an opportunity in the stock?The answer lies in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.